ACA Therapeutics is a clinical-stage biopharmaceutical company dedicated to resolving the fundamental drivers of cancer and chronic diseases. Unlike traditional models focused on lifelong symptom management, we utilize our proprietary Upstream-Midstream-Downstream (UMD) Framework to support more comprehensive, system-based therapeutic approaches.

Our mission is to develop accessible, high‑impact therapies that restore the body’s natural immune and physiological balance, enabling patients to move beyond lifelong symptom‑directed treatments. By reducing chronic inflammation and re‑establishing healthy system function, our platform is designed to lighten the burden of existing therapies — lowering doses, extending intervals, and ultimately reducing long‑term dependence on “forever medications.”